title: Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
abstract: OBJECTIVE
  To assess both feasibility and short term outcomes of a population based colorectal cancer screening programme using a biennial guaiac based faecal occult blood test (gFOBT).
  
  
  METHODS
  All participants were invited by mail to take part in a screening programme using a non-rehydrated gFOBT. The gFOBTs were first provided by general practitioners (GPs) and then directly mailed to individuals who failed to comply after two invitations. The setting was a French administrative district: Haut-Rhin (710,000 inhabitants). 182,981 residents aged 50-74 years were invited to participate.
  
  
  RESULTS
  19,274 people (10.5%) were excluded from gFOBT screening and 90,706 completed a gFOBT, so that the participation rate was 55.4% of those eligible. 76.5% of the completed gFOBTs were provided by GPs and 15.5% by direct mailing. The gFOBT positivity rate was 3.4%. The positive predictive value was 42.7% for neoplasia (women 30.8%, men 52.5%), 23.6% for advanced adenoma, and 7.6% for cancer. The number of normal colonoscopic procedures (without neoplasia) needed to be performed for each colonoscopy detecting an advanced neoplasia was 1.8, lower in men (1.2) than in women (3.4), and decreasing with age. Detection rates for neoplasia and cancer were 12.8 and 2.3 per 1000 people screened. 206 adenocarcinomas were detected: 47.6% were stage I and 23.8% stage II. The direct cost was estimated at euro 29.3 per screened person and euro 13,466 per cancer detected.
  
  
  CONCLUSIONS
  Participation and diagnostic yield of controlled trials of gFOBT screening are reproducible in the real world at an acceptable cost through an organised population based programme involving GPs.
authors.affiliation: Médecine A, Hôpital Pasteur, 39 avenue de la Liberté, 68024, Colmar, France. bernard.denis@ch-colmar.rss.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Denis
authors.forename: Marcel
authors.initials: M
authors.lastname: Ruetsch
authors.forename: Patrick
authors.initials: P
authors.lastname: Strentz
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Vogel
authors.forename: Francis
authors.initials: F
authors.lastname: Guth
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Boyaval
authors.forename: Xavier
authors.initials: X
authors.lastname: Pagnon
authors.forename: Jean François
authors.initials: JF
authors.lastname: Ebelin
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gendre
authors.forename: Philippe
authors.initials: P
authors.lastname: Perrin
mesh_terms: D000368:Aged; D003113:Colonoscopy / Q000191:economics / Q000379:methods* / Q000706:statistics & numerical data; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D005240:Feasibility Studies; D005260:Female; D006138:Guaiac; D006801:Humans; D007120:Immunochemistry; D007202:Indicators and Reagents; D008297:Male; D008403:Mass Screening / Q000191:economics*; D008875:Middle Aged; D009780:Occult Blood; D010865:Pilot Projects; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D007202:Indicators and Reagents; D006138:Guaiac